April 11, 2017 — IBA Molecular announced that it has merged with previous acquisition Mallinckrodt Nuclear Medicine LLC to form the new company Curium.
The new entity delivers diagnostic and therapeutic solutions to over 14 million people from a global network of 21 manufacturing centers; this includes one molybdenum facility, three large single-photon emission computed tomography (SPECT) facilities, and close to 40 SPECT and positron emission tomography (PET) radiopharmacies.
IBA Molecular acquired the Nuclear Medicine portion of Mallinckrodt in January, completing a process that began in August 2016. The acquisition included Mallinckrodt’s manufacturing operations in the United States and the Netherlands, according to the St. Louis Business Journal.
For more information: www.curiumpharma.com
July 30, 2024 
